{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:00:03Z","timestamp":1790557203847,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,12]]},"DOI":"10.7759\/cureus.36041","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T14:09:21Z","timestamp":1678630161000},"source":"Crossref","is-referenced-by-count":16,"title":["From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment"],"prefix":"10.7759","author":[{"given":"Prabhav Kashyap","family":"Godavarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Puli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2016.1178065","article-title":"Helicobacter pylori therapy: a paradigm shift","volume":"14","author":"Graham DY","year":"2016","unstructured":"Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016, 14:577-85. 10.1080\/14787210.2016.1178065","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640615617358","article-title":"Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events","volume":"4","author":"McFarland LV","year":"2016","unstructured":"McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016, 4:546-61. 10.1177\/2050640615617358","journal-title":"United European Gastroenterol J"},{"key":"ref3","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. (2017). http.\/\/remed.org\/wp-content\/uploads\/2017\/03\/lobal-priority-list-of-antibiotic-resistant-bacteria-2017.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000519413","article-title":"The ideal Helicobacter pylori treatment for the present and the future","volume":"103","author":"Suzuki S","year":"2022","unstructured":"Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2022, 103:62-8. 10.1159\/000519413","journal-title":"Digestion"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042220-020814","article-title":"Diagnosis and treatment of Helicobacter pylori infection","volume":"73","author":"Lee YC","year":"2022","unstructured":"Lee YC, Dore MP, Graham DY. Diagnosis and treatment of Helicobacter pylori infection. Annu Rev Med. 2022, 73:183-95. 10.1146\/annurev-med-042220-020814","journal-title":"Annu Rev Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100671","article-title":"Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship","volume":"9","author":"Graham DY","year":"2020","unstructured":"Graham DY. Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics (Basel). 2020, 9:671. 10.3390\/antibiotics9100671","journal-title":"Antibiotics (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF01297451","article-title":"Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries","volume":"36","author":"Graham DY","year":"1991","unstructured":"Graham DY, Adam E, Reddy GT, et al.. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci. 1991, 36:1084-8. 10.1007\/BF01297451","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis","volume":"161","author":"Rokkas T","year":"2021","unstructured":"Rokkas T, Gisbert JP, Malfertheiner P, et al.. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology. 2021, 161:495-507.e4. 10.1053\/j.gastro.2021.04.012","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102091","article-title":"What is new in Helicobacter pylori diagnosis. An overview","volume":"10","author":"Dore MP","year":"2021","unstructured":"Dore MP, Pes GM. What is new in Helicobacter pylori diagnosis. An overview. J Clin Med. 2021, 10:2091. 10.3390\/jcm10102091","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i32.4629","article-title":"Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing","volume":"25","author":"Pohl D","year":"2019","unstructured":"Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol. 2019, 25:4629-60. 10.3748\/wjg.v25.i32.4629","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012080.pub2","article-title":"Non-invasive diagnostic tests for Helicobacter pylori infection","volume":"3","author":"Best LM","year":"2018","unstructured":"Best LM, Takwoingi Y, Siddique S, et al.. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018, 3:CD012080. 10.1002\/14651858.CD012080.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano K","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al.. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015, 64:1353-67. 10.1136\/gutjnl-2015-309252","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.03.013","article-title":"Houston Consensus Conference on testing for Helicobacter pylori infection in the United States","volume":"16","author":"El-Serag HB","year":"2018","unstructured":"El-Serag HB, Kao JY, Kanwal F, et al.. Houston Consensus Conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol. 2018, 16:992-1002.e6. 10.1016\/j.cgh.2018.03.013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322368","article-title":"Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus","volume":"69","author":"Liou JM","year":"2020","unstructured":"Liou JM, Malfertheiner P, Lee YC, et al.. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020, 69:2093-112. 10.1136\/gutjnl-2020-322368","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314744","article-title":"Illusions regarding Helicobacter pylori clinical trials and treatment guidelines","volume":"66","author":"Graham DY","year":"2017","unstructured":"Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017, 66:2043-6. 10.1136\/gutjnl-2017-314744","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i16.1907","article-title":"Development of Helicobacter pylori treatment: how do we manage antimicrobial resistance?","volume":"25","author":"Suzuki S","year":"2019","unstructured":"Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: how do we manage antimicrobial resistance?. World J Gastroenterol. 2019, 25:1907-12. 10.3748\/wjg.v25.i16.1907","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12698","article-title":"Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan","volume":"25","author":"Horie R","year":"2020","unstructured":"Horie R, Handa O, Ando T, et al.. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. Helicobacter. 2020, 25:e12698. 10.1111\/hel.12698","journal-title":"Helicobacter"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324032","article-title":"Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community","volume":"70","author":"Megraud F","year":"2021","unstructured":"Megraud F, Bruyndonckx R, Coenen S, et al.. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021, 70:1815-22. 10.1136\/gutjnl-2021-324032","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000223","article-title":"Impact of previous exposure to macrolide antibiotics on Helicobacter pylori infection treatment outcomes","volume":"114","author":"Boltin D","year":"2019","unstructured":"Boltin D, Levi Z, Gingold-Belfer R, et al.. Impact of previous exposure to macrolide antibiotics on Helicobacter pylori infection treatment outcomes. Am J Gastroenterol. 2019, 114:900-6. 10.14309\/ajg.0000000000000223","journal-title":"Am J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.12.001","article-title":"The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use","volume":"48","author":"Lim SG","year":"2016","unstructured":"Lim SG, Park RW, Shin SJ, et al.. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis. 2016, 48:385-90. 10.1016\/j.dld.2015.12.001","journal-title":"Dig Liver Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03179.x","article-title":"Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy","volume":"25","author":"Tong JL","year":"2007","unstructured":"Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007, 25:155-68. 10.1111\/j.1365-2036.2006.03179.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02274.x","article-title":"Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial","volume":"20","author":"Nista EC","year":"2004","unstructured":"Nista EC, Candelli M, Cremonini F, et al.. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004, 20:1181-8. 10.1111\/j.1365-2036.2004.02274.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00716.x","article-title":"Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication","volume":"14","author":"Zou J","year":"2009","unstructured":"Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009, 14:449-59. 10.1111\/j.1523-5378.2009.00716.x","journal-title":"Helicobacter"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00168","article-title":"Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance","volume":"7","author":"Hu Y","year":"2017","unstructured":"Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017, 7:168. 10.3389\/fcimb.2017.00168","journal-title":"Front Cell Infect Microbiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.026","article-title":"Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship","volume":"20","author":"Graham DY","year":"2021","unstructured":"Graham DY, Liou JM. Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin Gastroenterol Hepatol. 2021, 20:973-83.e1. 10.1016\/j.cgh.2021.03.026","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/144015-from-antibiotic-resistance-to-antibiotic-renaissance-a-new-era-in-helicobacter-pylori-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:03Z","timestamp":1707508503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/144015-from-antibiotic-resistance-to-antibiotic-renaissance-a-new-era-in-helicobacter-pylori-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,12]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.36041","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,12]]}}}